• Je něco špatně v tomto záznamu ?

Activity and safety of the multi-target tyrosine kinase inhibitor cabozantinib in patients with metastatic gastrointestinal stromal tumour after treatment with imatinib and sunitinib: European Organisation for Research and Treatment of Cancer phase II trial 1317 'CaboGIST'

P. Schöffski, O. Mir, B. Kasper, Z. Papai, JY. Blay, A. Italiano, C. Benson, K. Kopeckova, N. Ali, P. Dileo, A. LeCesne, F. Menge, S. Cousin, E. Wardelmann, A. Wozniak, S. Marreaud, S. Litiere, F. Zaffaroni, A. Nzokirantevye, I. Vanden Bempt, H....

. 2020 ; 134 (-) : 62-74. [pub] 20200526

Jazyk angličtina Země Velká Británie

Typ dokumentu klinické zkoušky, fáze II, časopisecké články, multicentrická studie, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc20028048

BACKGROUND: Gastrointestinal stromal tumour (GIST) is commonly treated with tyrosine kinase inhibitors (TKIs), but most patients ultimately develop secondary resistance. Cabozantinib, a multi-targeted TKI inhibitor, has activity in patient-derived GIST mouse xenograft models and can overcome compensatory MET signalling occurring on TKI treatment. European Organisation for Treatment of Cancer (EORTC) 1317 'CaboGIST' assessed the safety and activity of cabozantinib in patients with GIST who had progressed on imatinib and sunitinib. METHODS: In this multi-center, open label, single arm phase II study, eligible GIST patients received oral cabozantinib (60 mg) once daily. Primary end-point was the progression-free survival rate at 12 weeks assessed by the local investigator per Response Evaluation Criteria in Solid Tumours 1·1. If at least 21 of the first 41 eligible and evaluable patients were progression-free at week 12, the activity of cabozantinib was sufficient to warrant further exploration according to the A'Hern one-stage study design. FINDINGS: A total of 50 eligible patients started treatment between 02/2017 and 08/2018, including four (8%) still continuing cabozantinib at clinical cut-off (09/2019). The number of 3-weekly treatment cycles ranged from 1 to 30. Among the first 41 eligible and evaluable patients, 24 were progression-free at week 12 (58·5%, 95% confidence interval [CI] 42·0-74·0%). Among all 50 patients, 30 were progression-free at week 12 (60%, 95% CI 45-74%). Seven patients achieved a partial response (14%, 95% CI 6-27%), and 34 had stable disease (68%, 95% CI 53-80%) as best response. Progression was seen in eight patients (16%, 95% CI 7-29%), and one was not evaluable. Disease control was achieved in 41 patients (82%, 95% CI 69-91%). Median progression-free survival was 5·5 months (95% CI 3·6-6·9). The most common adverse events were diarrhoea (76%), palmar-plantar erythrodysesthesia syndrome (60%), fatigue (50%), hypertension (42%), weight loss (40%) and oral mucositis (30%), with 32 (64%) patients requiring dose reductions, 27 (54%) having treatment interruptions and no cabozantinib-related deaths observed. INTERPRETATION: EORTC 1317 met its primary end-point, with 24/41 patients being progression-free at week 12 of treatment. The objective response was 14% with an encouraging disease control rate of 82%. Results of this trial confirm preclinical findings and warrant further exploration of cabozantinib in GIST. CLINICAL TRIAL NUMBERS: EORTC 1317, NCT02216578, EudraCT 2014-000501-13.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20028048
003      
CZ-PrNML
005      
20210114152856.0
007      
ta
008      
210105s2020 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.ejca.2020.04.021 $2 doi
035    __
$a (PubMed)32470848
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Schöffski, Patrick $u Department of General Medical Oncology, University Hospitals Leuven, Leuven Cancer Institute, and Department of Oncology, KU Leuven, Laboratory of Experimental Oncology, Leuven, Belgium. Electronic address: patrick.schoffski@uzleuven.be.
245    10
$a Activity and safety of the multi-target tyrosine kinase inhibitor cabozantinib in patients with metastatic gastrointestinal stromal tumour after treatment with imatinib and sunitinib: European Organisation for Research and Treatment of Cancer phase II trial 1317 'CaboGIST' / $c P. Schöffski, O. Mir, B. Kasper, Z. Papai, JY. Blay, A. Italiano, C. Benson, K. Kopeckova, N. Ali, P. Dileo, A. LeCesne, F. Menge, S. Cousin, E. Wardelmann, A. Wozniak, S. Marreaud, S. Litiere, F. Zaffaroni, A. Nzokirantevye, I. Vanden Bempt, H. Gelderblom,
520    9_
$a BACKGROUND: Gastrointestinal stromal tumour (GIST) is commonly treated with tyrosine kinase inhibitors (TKIs), but most patients ultimately develop secondary resistance. Cabozantinib, a multi-targeted TKI inhibitor, has activity in patient-derived GIST mouse xenograft models and can overcome compensatory MET signalling occurring on TKI treatment. European Organisation for Treatment of Cancer (EORTC) 1317 'CaboGIST' assessed the safety and activity of cabozantinib in patients with GIST who had progressed on imatinib and sunitinib. METHODS: In this multi-center, open label, single arm phase II study, eligible GIST patients received oral cabozantinib (60 mg) once daily. Primary end-point was the progression-free survival rate at 12 weeks assessed by the local investigator per Response Evaluation Criteria in Solid Tumours 1·1. If at least 21 of the first 41 eligible and evaluable patients were progression-free at week 12, the activity of cabozantinib was sufficient to warrant further exploration according to the A'Hern one-stage study design. FINDINGS: A total of 50 eligible patients started treatment between 02/2017 and 08/2018, including four (8%) still continuing cabozantinib at clinical cut-off (09/2019). The number of 3-weekly treatment cycles ranged from 1 to 30. Among the first 41 eligible and evaluable patients, 24 were progression-free at week 12 (58·5%, 95% confidence interval [CI] 42·0-74·0%). Among all 50 patients, 30 were progression-free at week 12 (60%, 95% CI 45-74%). Seven patients achieved a partial response (14%, 95% CI 6-27%), and 34 had stable disease (68%, 95% CI 53-80%) as best response. Progression was seen in eight patients (16%, 95% CI 7-29%), and one was not evaluable. Disease control was achieved in 41 patients (82%, 95% CI 69-91%). Median progression-free survival was 5·5 months (95% CI 3·6-6·9). The most common adverse events were diarrhoea (76%), palmar-plantar erythrodysesthesia syndrome (60%), fatigue (50%), hypertension (42%), weight loss (40%) and oral mucositis (30%), with 32 (64%) patients requiring dose reductions, 27 (54%) having treatment interruptions and no cabozantinib-related deaths observed. INTERPRETATION: EORTC 1317 met its primary end-point, with 24/41 patients being progression-free at week 12 of treatment. The objective response was 14% with an encouraging disease control rate of 82%. Results of this trial confirm preclinical findings and warrant further exploration of cabozantinib in GIST. CLINICAL TRIAL NUMBERS: EORTC 1317, NCT02216578, EudraCT 2014-000501-13.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a anilidy $x aplikace a dávkování $7 D000813
650    _2
$a protokoly protinádorové kombinované chemoterapie $x terapeutické užití $7 D000971
650    _2
$a chemorezistence $x účinky léků $7 D019008
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a následné studie $7 D005500
650    _2
$a gastrointestinální nádory $x farmakoterapie $x patologie $7 D005770
650    _2
$a gastrointestinální stromální tumory $x farmakoterapie $x sekundární $7 D046152
650    _2
$a lidé $7 D006801
650    _2
$a imatinib mesylát $x aplikace a dávkování $7 D000068877
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a prognóza $7 D011379
650    _2
$a inhibitory proteinkinas $x terapeutické užití $7 D047428
650    _2
$a pyridiny $x aplikace a dávkování $7 D011725
650    12
$a záchranná terapie $7 D016879
650    _2
$a sunitinib $x aplikace a dávkování $7 D000077210
650    _2
$a míra přežití $7 D015996
655    _2
$a klinické zkoušky, fáze II $7 D017427
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Mir, Olivier $u Department of Medical Oncology, Gustave Roussy, Villejuif, France.
700    1_
$a Kasper, Bernd $u Sarcoma Unit, Interdisciplinary Tumor Center Mannheim, Mannheim University Medical Center, Mannheim, Germany.
700    1_
$a Papai, Zsuzsanna $u State Health Center, Oncology Department, Budapest, Hungary.
700    1_
$a Blay, Jean-Yves $u Department of Medical Oncology, Centre Léon Bérard, NETSARC+, LYRICAN, and Université Claude Bernard Lyon I, Lyon, France.
700    1_
$a Italiano, Antoine $u Sarcoma Unit, Institut Bergonié, Bordeaux, France.
700    1_
$a Benson, Charlotte $u Royal Marsden Hospital, London, United Kingdom.
700    1_
$a Kopeckova, Katerina $u Department of Oncology, Motol University Hospital, Czech Republic.
700    1_
$a Ali, Nasim $u Clatterbridge Cancer Centre, Wirral, United Kingdom.
700    1_
$a Dileo, Palma $u Sarcoma Unit, University College London, United Kingdom.
700    1_
$a LeCesne, Axel $u Department of Medical Oncology, Gustave Roussy, Villejuif, France.
700    1_
$a Menge, Franka $u Sarcoma Unit, Interdisciplinary Tumor Center Mannheim, Mannheim University Medical Center, Mannheim, Germany.
700    1_
$a Cousin, Sophie $u Sarcoma Unit, Institut Bergonié, Bordeaux, France.
700    1_
$a Wardelmann, Eva $u University Hospital, Münster, Germany.
700    1_
$a Wozniak, Agnieszka $u Department of General Medical Oncology, University Hospitals Leuven, Leuven Cancer Institute, and Department of Oncology, KU Leuven, Laboratory of Experimental Oncology, Leuven, Belgium.
700    1_
$a Marreaud, Sandrine $u European Organization for Research and Treatment of Cancer, Brussels, Belgium.
700    1_
$a Litiere, Saskia $u European Organization for Research and Treatment of Cancer, Brussels, Belgium.
700    1_
$a Zaffaroni, Facundo $u European Organization for Research and Treatment of Cancer, Brussels, Belgium.
700    1_
$a Nzokirantevye, Axelle $u European Organization for Research and Treatment of Cancer, Brussels, Belgium.
700    1_
$a Vanden Bempt, Isabelle $u Department of Human Genetics, KU Leuven, University Hospitals Leuven, Leuven, Belgium.
700    1_
$a Gelderblom, Hans $u Department of Medical Oncology, Leiden University Medical Center, Leiden, Netherlands.
773    0_
$w MED00009626 $t European journal of cancer (Oxford, England : 1990) $x 1879-0852 $g Roč. 134, č. - (2020), s. 62-74
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32470848 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20210105 $b ABA008
991    __
$a 20210114152853 $b ABA008
999    __
$a ok $b bmc $g 1608383 $s 1119228
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 134 $c - $d 62-74 $e 20200526 $i 1879-0852 $m European journal of cancer $n Eur J Cancer $x MED00009626
LZP    __
$a Pubmed-20210105

Najít záznam

Citační ukazatele

Možnosti archivace